Xavier Roussel

453 total citations
13 papers, 84 citations indexed

About

Xavier Roussel is a scholar working on Genetics, Oncology and Hematology. According to data from OpenAlex, Xavier Roussel has authored 13 papers receiving a total of 84 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 5 papers in Oncology and 4 papers in Hematology. Recurrent topics in Xavier Roussel's work include CAR-T cell therapy research (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Virus-based gene therapy research (3 papers). Xavier Roussel is often cited by papers focused on CAR-T cell therapy research (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Virus-based gene therapy research (3 papers). Xavier Roussel collaborates with scholars based in France, Luxembourg and United States. Xavier Roussel's co-authors include Christophe Ferrand, Marina Deschamps, Walid Warda, Étienne Daguindau, Éric Deconinck, Yahya Salma, Ana Berceanu, Florian Renosi, Yohan Desbrosses and Marie Favier and has published in prestigious journals such as Blood, Advanced Science and British Journal of Haematology.

In The Last Decade

Xavier Roussel

11 papers receiving 82 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xavier Roussel France 6 41 24 22 18 17 13 84
Pere Barba Spain 4 59 1.4× 13 0.5× 14 0.6× 11 0.6× 13 0.8× 17 67
Alison J. Potter Australia 6 33 0.8× 34 1.4× 31 1.4× 19 1.1× 11 0.6× 17 97
Nora Liebers Germany 8 49 1.2× 41 1.7× 15 0.7× 21 1.2× 16 0.9× 16 108
Chung Mun Alice Lin United Kingdom 4 34 0.8× 12 0.5× 15 0.7× 35 1.9× 12 0.7× 9 129
Sophia Bylsma United States 3 98 2.4× 33 1.4× 37 1.7× 24 1.3× 18 1.1× 5 118
Sascha Kretschmann Germany 5 79 1.9× 25 1.0× 6 0.3× 56 3.1× 15 0.9× 8 109
Gerulf Hänel Germany 5 39 1.0× 21 0.9× 20 0.9× 53 2.9× 4 0.2× 15 92
Alexander M. Leipold Germany 4 38 0.9× 14 0.6× 9 0.4× 13 0.7× 8 0.5× 7 63
Alice Piapi United Kingdom 5 49 1.2× 37 1.5× 18 0.8× 28 1.6× 19 1.1× 8 96
Seishi Ogawa Japan 5 31 0.8× 58 2.4× 14 0.6× 24 1.3× 10 0.6× 26 114

Countries citing papers authored by Xavier Roussel

Since Specialization
Citations

This map shows the geographic impact of Xavier Roussel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier Roussel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier Roussel more than expected).

Fields of papers citing papers by Xavier Roussel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xavier Roussel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier Roussel. The network helps show where Xavier Roussel may publish in the future.

Co-authorship network of co-authors of Xavier Roussel

This figure shows the co-authorship network connecting the top 25 collaborators of Xavier Roussel. A scholar is included among the top collaborators of Xavier Roussel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xavier Roussel. Xavier Roussel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
2.
Roussel, Xavier, Sabeha Biichlé, Maxime Fredon, et al.. (2025). New leads to enhance tagraxofusp efficacy in pDC-AML. PubMed. 2(2). 100066–100066.
3.
Laribi, Kamel, Stéphanie Poulain, Lise Willems, et al.. (2024). Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO). British Journal of Haematology. 204(6). 2233–2236. 6 indexed citations
4.
Warda, Walid, et al.. (2023). CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans. Current Research in Translational Medicine. 71(2). 103385–103385. 12 indexed citations
5.
Roussel, Xavier, Sabeha Biichlé, Maxime Fredon, et al.. (2023). Analysis of Tagraxofusp Activity in AML-Pdc As a Single Agent and in Combination with BCL2 Inhibitors. Blood. 142(Supplement 1). 2783–2783. 1 indexed citations
6.
Roussel, Xavier, et al.. (2022). Plasmacytoid Dendritic Cells, a Novel Target in Myeloid Neoplasms. Cancers. 14(14). 3545–3545. 6 indexed citations
9.
Roussel, Xavier, Étienne Daguindau, Ana Berceanu, et al.. (2020). Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. Frontiers in Oncology. 10. 599933–599933. 16 indexed citations
10.
Roussel, Xavier, et al.. (2020). Pyogenic Granuloma During Ibrutinib Therapy for B-Cell Neoplasia. JCO Oncology Practice. 16(12). 834–836. 2 indexed citations
12.
13.
Roussel, Xavier, Étienne Daguindau, Ana Berceanu, et al.. (2019). Altered thymic CD4+ T-cell recovery after allogeneic hematopoietic stem cell transplantation is critical for nocardiosis. Current Research in Translational Medicine. 67(4). 135–143. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026